Table 4.
Clinical management of FN based on expert opinion
| Drug name | Patients treated among those developing FN (%)a | Total daily dose (mg) | Average duration (days) |
|---|---|---|---|
| Piperacillin + tazobactam | 34% | 16 000 | 6.1 |
| Amikacin | 26% | 1 000 to 1 500 | 4.1 |
| Ceftazidime | 18% | 2 625 to 4 000 | 5 |
| Amoxycillin + clavulanic acid | 17% | 6 000 | 5.4 |
| Cefepime | 14% | 6 000 to 16 000 | 5.8 |
| Filgrastim | 13% | 0.3 | 4.5 |
| Fluconazole | 8% | 200 to 400 | 6.5 |
| Ciprofloxacin | 7% | 0.3 | 5.5 |
| Procedure name | Patients treated among those developing FN (%)* | Average frequency of procedure | |
| Chest X-ray | 80% | 1.2 | |
| Microbiological tests | 78% | 2.4 | |
| Abdominal echography | 7% | 1.0 | |
| Hospitalization by usage of PP/SP | Patients hospitalized among those developing FN (%) | Average [range] LOS (days) | |
| No G-CSF prophylaxis | 48% | 4.2 [3-7] | |
| PP | 19% | 1.5 [1-2] | |
| SP | 20% | 3.3 [3-7] | |
Only resources with frequencies >5% are reported. The table is based on oncologists' answers. The participating hematologists reported similar findings (results not shown).
LOS: length of stay
aObtained by multiplying the percentage of experts mentioning the drug/test by the average proportion of patients receiving this drug/test as estimated by these experts.